검색
Fortress Biotech Inc
FBIO관심 목록에 추가
2.410USD
+0.110+4.78%
종가 05/15, 16:00（ET）시세는 15분 지연됩니다
80.06M시가총액
0.63P/E TTM
자세한 내용은 Fortress Biotech Inc 회사
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Fortress Biotech Inc 정보
종목 코드 FBIO
회사 이름Fortress Biotech Inc
상장일Nov 17, 2011
CEORosenwald (Lindsay A)
직원 수101
유형Ordinary Share
회계 연도 종료Nov 17
주소1111 Kane Concourse
도시BAY HARBOR ISLANDS
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호33154
전화17816524500
웹사이트https://www.fortressbiotech.com/
종목 코드 FBIO
상장일Nov 17, 2011
CEORosenwald (Lindsay A)
Fortress Biotech Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
4.59M
--
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Vice Chairman - Strategic Development, Director
Executive Vice Chairman - Strategic Development, Director
2.28M
--
Mr. Dov Klein, CPA
Mr. Dov Klein, CPA
Independent Director
Independent Director
130.10K
+57.91%
Mr. David Jin
Mr. David Jin
Chief Financial Officer and Head of Corporate Development
Chief Financial Officer and Head of Corporate Development
21.57K
+36.93%
Dr. Lucy Lu, M.D.
Dr. Lucy Lu, M.D.
Chief Strategy Officer
Chief Strategy Officer
5.22K
--
Dr. Jimmie Harvey, Jr., M.D.
Dr. Jimmie Harvey, Jr., M.D.
Independent Director
Independent Director
--
--
Mr. J. Jay Lobell, J.D.
Mr. J. Jay Lobell, J.D.
Independent Director
Independent Director
--
--
Mr. Malcolm I. Hoenlein, Ph.D.
Mr. Malcolm I. Hoenlein, Ph.D.
Independent Director
Independent Director
--
--
Mr. Kevin L. Lorenz, J.D.
Mr. Kevin L. Lorenz, J.D.
Independent Director
Independent Director
--
--
Ms. Jaclyn Jaffe
Ms. Jaclyn Jaffe
Investor Relations
Investor Relations
--
--
이름
이름/직위
직위
주식 보유
변동
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
4.59M
--
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Vice Chairman - Strategic Development, Director
Executive Vice Chairman - Strategic Development, Director
2.28M
--
Mr. Dov Klein, CPA
Mr. Dov Klein, CPA
Independent Director
Independent Director
130.10K
+57.91%
Mr. David Jin
Mr. David Jin
Chief Financial Officer and Head of Corporate Development
Chief Financial Officer and Head of Corporate Development
21.57K
+36.93%
Dr. Lucy Lu, M.D.
Dr. Lucy Lu, M.D.
Chief Strategy Officer
Chief Strategy Officer
5.22K
--
Dr. Jimmie Harvey, Jr., M.D.
Dr. Jimmie Harvey, Jr., M.D.
Independent Director
Independent Director
--
--
수익 분석
통화: USD마지막 업데이트: Apr 2, 2025
통화: USD마지막 업데이트: Apr 2, 2025
FY2023
FY2023Q4
FY2022
FY2022Q4
FY2021
FY2019
사업별USD
이름
수익
비율
Targadox®
3.20M
3.79%
Exelderm®
2.40M
2.83%
Ximino®
287.00K
0.34%
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
사업별USD
이름
수익
비율
Targadox®
3.20M
3.79%
Exelderm®
2.40M
2.83%
Ximino®
287.00K
0.34%
주식 보유 통계
마지막 업데이트: Mon, May 11
마지막 업데이트: Mon, May 11
주주
주주 유형
주주
주주
비율
Rosenwald (Lindsay A)
13.81%
Weiss (Michael S)
6.85%
Opaleye Management Inc.
3.28%
Vanguard Capital Management, LLC
2.91%
Summit Financial, LLC
1.32%
기타
71.83%
주주
주주
비율
Rosenwald (Lindsay A)
13.81%
Weiss (Michael S)
6.85%
Opaleye Management Inc.
3.28%
Vanguard Capital Management, LLC
2.91%
Summit Financial, LLC
1.32%
기타
71.83%
주주 유형
주주
비율
Individual Investor
22.79%
Investment Advisor
9.55%
Hedge Fund
5.62%
Investment Advisor/Hedge Fund
2.48%
Research Firm
0.49%
Venture Capital
0.04%
기타
59.02%
기관 주식 보유
마지막 업데이트: Wed, Apr 1
마지막 업데이트: Wed, Apr 1
보고 기간
기관 수
보유 주식
비율
변동
2026Q1
113
6.02M
18.14%
-871.67K
2025Q4
92
4.96M
26.50%
--
2025Q3
107
4.96M
27.33%
--
2025Q2
114
4.96M
27.45%
+47.82K
2025Q1
116
4.91M
27.75%
-3.29M
2024Q4
121
4.82M
26.63%
+370.47K
2024Q3
123
4.48M
24.67%
+822.95K
2024Q2
130
3.66M
27.39%
+620.10K
2024Q1
155
3.04M
28.91%
-2.56M
2023Q4
162
4.72M
15.96%
+3.18M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Rosenwald (Lindsay A)
4.59M
14.78%
+475.42K
+11.56%
Mar 18, 2026
Weiss (Michael S)
2.28M
7.33%
+475.42K
+26.40%
Mar 18, 2026
Opaleye Management Inc.
1.09M
3.51%
+1.09M
--
Dec 31, 2025
Summit Financial, LLC
439.93K
1.42%
-4.82K
-1.08%
Dec 31, 2025
Shikiar Asset Management, Inc.
278.47K
0.9%
--
--
Dec 31, 2025
Geode Capital Management, L.L.C.
262.49K
0.85%
+18.07K
+7.39%
Dec 31, 2025
Northern Trust Investments, Inc.
239.53K
0.77%
+18.90K
+8.56%
Dec 31, 2025
Susquehanna International Group, LLP
229.78K
0.74%
-126.40K
-35.49%
Dec 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
iShares Micro-Cap ETF
0.01%
Fidelity Enhanced Small Cap ETF
0%
iShares Micro-Cap ETF
비율0.01%
Fidelity Enhanced Small Cap ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
날짜
배당락일
유형
비율
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
